The CONDOR trial was a randomized, phase II study that assessed durvalumab monotherapy, tremelimumab (a CTLA-4 monoclonal antibody) monotherapy, and combination tremelimumab and durvalumab in 267 patients with refractory RM HNC and low/negative PD-L1 tumor expression. This evidence concerns the gene CD274 and neoplasm.